Drug Profile
Sonelokimab - MoonLake Immunotherapeutics
Alternative Names: ALX 0761; Anti-IL-17A/F Nanobody; M 1095; MSB-0010841; Nanobody® IL-17 A/F inhibitor; SonelokinabLatest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Ablynx
- Developer Avillion; MoonLake Immunotherapeutics
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Single-domain antibodies; Skin disorder therapies
- Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hidradenitis suppurativa; Psoriasis; Psoriatic arthritis
- Phase I Ankylosing spondylitis
Most Recent Events
- 10 Mar 2024 Updated efficacy and safety data from the phase-II ARGO trial in Psoriasis arthritis release by MoonLake Immunotherapeutics
- 10 Mar 2024 MoonLake Immunotherapeutics plans a phase II trial for Palmoplantar pustulosis
- 28 Feb 2024 MoonLake plans an end-of-Phase II meeting with the FDA for psoriatic arthritis (PsA) program in second quarter of 2024